Bacteria transplant plus chemo and immunotherapy for advanced pancreatic cancer
This trial tests whether giving a healthy bacteria transplant along with chemotherapy and an immunotherapy drug can help people with advanced pancreatic cancer. The treatment aims to boost the body's immune system to fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have pancreatic cancer that is locally advanced (has not spread to distant organs) and cannot be removed with surgery.
- You have not had chemotherapy or other systemic treatment for your advanced cancer before.
- You have at least one tumor that can be measured on scans.
- Your organs (kidney, liver, heart, blood) are working well enough, based on routine tests.
- You are able to swallow whole capsules, and you have not taken strong oral antibiotics recently (within the washout period).
- You are able to take care of yourself (ECOG performance status 0 or 1) and expected to live at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a fecal microbiota transplant (FMT, a procedure to restore healthy gut bacteria) with an investigational immunotherapy (SHR-1701) and standard chemotherapy drugs (nab-paclitaxel and gemcitabine) as first treatment for advanced pancreatic cancer. The goal is to see if this combination slows tumor growth and helps you live longer.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
This trial tests a new type of immunotherapy (called Lm-LLO-TT) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and effective.
Hear when a new Locally Advanced Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.